British regulators on Thursday approved GlaxoSmithKline drug sotrovimab to treat those at high risk of developing severe COVID-19 symptoms, with the manufacturer saying it “retains activity” against the new Omicron variant.
The monoclonal antibody “was found to be safe and effective at reducing the risk of hospitalization and death in people with mild to moderate COVID-19 infection who are at an increased risk of developing severe disease,” said the Medicines and Healthcare products Regulatory Agency (MHRA).
Japan eases blanket ban on new incoming flights following Omicron fearsJapan has softened its suspension of all new incoming flight bookings to make it easier for citizens to return, the government said Thursday, a day ... Coronavirus
UAE reports its first case of COVID-19 variant OmicronThe UAE’s Ministry of Health detected on Wednesday the first case of the Omicron variant in the country, state news agency WAM reported.The new ... Coronavirus
Saudi Arabia detects first case of COVID-19 Omicron variant in KingdomSaudi Arabia’s Ministry of Health on Wednesday said a case of the COVID-19 Omicron variant was detected in the Kingdom in a citizen coming from a ... Coronavirus